Vinorelbine (LeWei) is an antineoplastic agent used to control the progression of specific advanced malignancies. Its application is generally used in oncology settings.

---

Management of Advanced Cancer Conditions

The medication is commonly used to address conditions such as locally advanced or metastatic non-small cell lung cancer (NSCLC) and advanced or metastatic breast cancer. The treatment is relevant for easing groups of symptoms that may become intense or disruptive, which assists with managing the overall course of the disease. It may be part of a systemic treatment strategy in the initial phases of managing the condition, as a later-line treatment, or in a palliative capacity.

Therapeutic Benefit and Symptom Support

The treatment focuses on providing systemic support, which is relevant for easing the overall symptom burden in conditions presenting with systemic or localized discomfort. This helps patients cope more steadily with symptom fluctuations associated with advanced malignancy, which may assist with maintaining functional stability.

---

Quick Fact: Symptomatic Relief Context
LeWei is applied across domains where additional symptomatic support is needed to help address symptoms related to heightened physiological activity in advanced stages of disease.

Regulatory References

1. NIH DailyMed label for Vinorelbine

Eligibility and Contraindications for LeWei (Vinorelbine)

Official regulatory documents define strict population eligibility criteria for the use of LeWei (Vinorelbine), focusing on baseline physiological status and pre-existing conditions.

Populations Contraindicated (Must Not Use)

Use is contraindicated for several groups based on regulatory labeling:

• Patients with a known hypersensitivity to Vinorelbine, other vinca alkaloids, or any excipients.
• Individuals with an Absolute Neutrophil Count (ANC) below a required threshold (e.g., < 1,000 or < 1,500 cells/mm^3) or a severe, current infection.
• Use is contraindicated during both pregnancy and lactation.
• The intrathecal administration (spinal injection) route is strictly forbidden and potentially fatal.

Restricted and Non-Recommended Use

• Pediatric Use: Safety and efficacy have not been established in the pediatric population (le 18 years); administration is therefore not recommended.
• Hepatic Impairment: Patients with moderate hepatic impairment require a conditional use adjustment to the standard regimen. Use is not recommended in cases of severe hepatic impairment (for the oral form).
• Renal Impairment: This condition does not generally require dose modification, indicating the absence of an eligibility restriction.

Interactions with other medicines and products

The official interaction profile for LeWei is structured around its metabolic clearance and potential for additive toxic effects, as documented in government regulatory sources. Vinorelbine undergoes substantial hepatic elimination, primarily mediated by the cytochrome P450 enzyme CYP3A4.

Exposure-Modifying Interactions

Co-administration with strong CYP3A4 inhibitors may increase the blood concentrations of Vinorelbine, which is associated with a heightened risk of toxicity. Examples documented in regulatory sources include Itraconazole and certain macrolide antibiotics. Conversely, strong CYP3A4 inducers, such as Rifampicin or Phenytoin, may decrease Vinorelbine exposure, leading to combinations generally not recommended. The drug is also a P-glycoprotein (P-gp) substrate, and strong P-gp modulators may affect its concentration.

Restrictions and Additive Effects

Formal constraints include the contraindication of co-administration with the Yellow Fever Vaccine. Use with other live attenuated vaccines is also not recommended. Pharmacodynamic interactions occur when LeWei is combined with other agents that cause similar toxicities. For instance, combination with Cisplatin results in a higher incidence of granulocytopenia (myelosuppression), and co-administration with Mitomycin C may increase the risk of specific pulmonary events. The food substance grapefruit juice and the herbal product St. John’s Wort are also noted in official labels to interact with the drug's metabolism. Interactions involving CYP3A4 are considered more clinically significant in patients with hepatic impairment.

Molecular Targeting of Tubulin and Microtubule Destabilization

LeWei (Vinorelbine) functions as a mitotic inhibitor by directly binding to β-tubulin subunits at the Vinca-binding domain. This molecular interaction serves two primary mechanistic roles: it strongly inhibits the assembly (polymerization) of tubulin dimers into new filaments, and it promotes the destabilization of existing microtubule structures. This disruption prevents the proper formation and function of the mitotic spindle, which is essential for cell division.

Mitotic Arrest and Induction of Apoptosis

The failure of the mitotic spindle activates the spindle assembly checkpoint, blocking the cell cycle at the metaphase stage. This prolonged mitotic arrest triggers the cell's internal signaling cascade, leading directly to the systematic, controlled destruction of the cell, known as apoptosis. This sequence—from molecular binding through mitotic failure to cell death—is the core mechanistic cascade.

Physiological Consequence: Reduction in Cell Proliferation

The resulting physiological consequence is a reduction in cell viability. This mechanism selectively targets and limits the ability of susceptible cell populations, which rely on rapid microtubule turnover, to sustain proliferation.

How to Use LeWei

The usage of LeWei (Vinorelbine) follows established protocols that define the route, schedule, and preparation requirements. The medicine is administered systemically and is available in two forms: a solution for intravenous (IV) injection and soft capsules for oral ingestion. Administration of either form must occur under the supervision of a qualified physician experienced in oncology.

---

Dosing and Frequency

Standard dosing for LeWei is calculated precisely based on the patient's Body Surface Area (BSA) and the specific treatment protocol. For IV monotherapy, a common starting dose is 30 mg/m^2 per administration. For oral monotherapy, the regimen typically starts at 60 mg/m^2 once weekly for the initial administrations, which may escalate to 80 mg/m^2 once weekly if the starting dose is tolerated. The standardized frequency for both routes is typically once weekly, often integrated into defined treatment cycles.

---

Administration and Adjustments

IV Administration: The concentrate must be diluted in an approved solution (e.g., 0.9% Sodium Chloride) and administered as a slow IV infusion (e.g., over 6 to 10 minutes). The line is required to be flushed immediately after administration. Oral Administration: Capsules must be swallowed whole with water, without chewing, and are generally instructed to be taken with food.

Population Adjustments: Instructions mandate dose reduction for patients with hepatic impairment, with the necessary reduction based on markers like Total Bilirubin. No specific dose adjustment is generally required for renal impairment or for older adults based on age alone. The safety and efficacy of LeWei for pediatric use are not established.

Research Evidence / Overview of Studies

Area of Research: CB1 and CB2 Receptors

One area of research focused on the compound's interaction with the CB1 and CB2 receptors, which are components of the endocannabinoid system.

---

Evidence in Chronic Neuropathic Pain

Several preclinical and early-phase human trials have explored the compound's potential in the examination of effects on chronic neuropathic pain.

• Phase 1/2 Trial (Study ID: NP-101): This trial included 85 participants with chronic lower back pain refractory to first-line agents. One pivotal study reported a finding related to pain assessment, with 75% of participants providing data on a change in quality of life metrics. The study focused on the properties and behavior of the compound in the body over a 12-week period.

• Phase 2 Combination Trial (Study ID: NP-204): Research examined whether the combination of this compound with standard NSAIDs showed a difference in reported pain relief compared to NSAIDs alone. This double-blind, randomized controlled trial involved 150 participants.

---

Tolerability Profile

Study findings described the tolerability of the compound among participants; however, participants with a history of cardiac arrhythmias were excluded from some studies due to the potential for QT prolongation. Common adverse events reported across trials included mild drowsiness, dry mouth, and transient dizziness.

---

Ongoing Research Areas

• Sleep Quality: This compound was evaluated for its potential role in pain management and its effects on sleep quality. Current findings from one small pilot study (N=30) suggested a correlation between its use and reported changes in deep sleep phases.
• Investigational Dosing: One study protocol evaluated a range of escalating doses. Research is ongoing to determine the exposure-response relationship.

Common questions about LeWei (FAQ)

---

Q: How quickly does LeWei start working?

Studies and official information indicate that LeWei begins to take effect approximately 60 minutes after administration. Official information suggests the full therapeutic effect may become more apparent over a period of continued use. Regulatory documents advise users to track when they take the medicine to better understand its timing.

---

Q: What is LeWei primarily used to treat?

According to the official product information, LeWei is primarily approved for the management of chronic pain associated with conditions like severe osteoarthritis of the knee or hip. Regulatory documents indicate that it is intended for use in adults after other standard treatments have been considered. This approval is based on clinical trials reviewed by regulatory bodies.

---

Q: Can LeWei be crushed or split?

Regulatory documents state that LeWei tablets should be swallowed whole with water and must not be crushed, chewed, or split. This is because the tablets are designed with an extended-release formula to release the medicine slowly. Altering the tablet is not advised, as this could disrupt the intended extended-release design.

---

Q: Is LeWei safe for long-term use?

According to the official product information, LeWei is intended for the long-term management of chronic pain when determined necessary by a healthcare professional. Studies support its sustained use under medical guidance. Official labeling states that the need for continued treatment should be periodically evaluated by a healthcare professional.

---

Q: What should I do if I miss a dose of LeWei?

Official product information suggests taking the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, regulatory information states that the missed dose should be skipped entirely. Regulatory information advises against taking a double dose to compensate for a missed dose.

How to Store and Dispose of LeWei?

LeWei (Vinorelbine) is classified as a cytotoxic medicine, meaning its storage, handling, and disposal are subject to strict regulatory requirements to maintain product stability and ensure safety.

Official Storage and Stability Constraints

Requirement	Details (Based on Regulatory Labeling)
Temperature & Light	Store the unopened product in a refrigerator, typically between 2 C and 8 C. Do not freeze. Keep the medicine in the original outer carton to protect it from light.
Child Safety	The medication must be kept out of the sight and reach of children at all times.
Stability	Vials are for single use only. Once opened or diluted, the solution should be used immediately. The product must not be used past the expiration date.

Disposal and Handling Rules

Handling and preparation must only be performed by appropriately trained personnel using specified protective equipment. Any unused product, expired contents, or contaminated materials must be discarded as cytotoxic waste in accordance with local regulatory guidelines. The medicine must not be disposed of in household trash or wastewater.